4 results
To determine the pharmacokinetic properties of a new elacridar formulation
- to evaluate the FVIIa activity PK of 2 CSL689 dose levels in subjects with congenital FVII deficiency- to determine the PK characteristics of FVIIa activity of CSL689- to evaluate the safety and tolerability of intravenous administration of CSL689
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
The objective of this pilot study is to demonstrate that NAVA ventilation is superior compared to pressure support and pressure control ventilation in work of breathing (expressed as pressure-time product) patient ventilator synchrony and other…